UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

The lancet oncology, 2016-12, Vol.17 (12), p.1683-1696

2016

Volltextzugriff (PDF)

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

Clinical cancer research, 2020-02, Vol.26 (4), p.970-977

2020

Volltextzugriff (PDF)

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Journal of clinical oncology, 2020-11, Vol.38 (31), p.3592-3603

2020

Volltextzugriff (PDF)

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Nature (London), 2014-11, Vol.515 (7528), p.563-567

2014

Volltextzugriff (PDF)

Programmed death ligand-1 expression in non-small cell lung cancer

Laboratory investigation, 2014-01, Vol.94 (1), p.107-116

2014

Volltextzugriff (PDF)

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2091-2108

2021

Volltextzugriff (PDF)

Oncolytic virus immunotherapy: future prospects for oncology

Journal for Immunotherapy of Cancer, 2018-12, Vol.6 (1), p.140-13, Article 140

2018

Volltextzugriff (PDF)

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

Clinical cancer research, 2018-04, Vol.24 (8), p.1872-1880

2018

Volltextzugriff (PDF)

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Clinical cancer research, 2016-09, Vol.22 (18), p.4539-4541

2016

Volltextzugriff (PDF)

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study

Journal of clinical oncology, 2018-06, Vol.36 (17), p.1675-1684

2018

Volltextzugriff (PDF)

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

The Journal of immunology (1950), 2015-02, Vol.194 (3), p.950-959

2015

Volltextzugriff (PDF)

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis

Journal of clinical oncology, 2017-04, Vol.35 (10), p.1070-1077

2017

Volltextzugriff (PDF)

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

American journal of kidney diseases, 2016-08, Vol.68 (2), p.287-291

2016

Volltextzugriff (PDF)

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

The lancet oncology, 2020-05, Vol.21 (5), p.655-663

2020

Volltextzugriff (PDF)

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-09, Vol.34 (25), p.2980-2987

2016

Volltextzugriff (PDF)

Immuno-thermal ablations - boosting the anticancer immune response

Journal for Immunotherapy of Cancer, 2017-10, Vol.5 (1), p.78-78, Article 78

2017

Volltextzugriff (PDF)

Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2019-12, Vol.14 (12), p.2084-2096

2019

Volltextzugriff (PDF)

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Journal of clinical oncology, 2019-02, Vol.37 (4), p.278-285

2019

Volltextzugriff (PDF)

Programmed death ligand-1 expression in non-small cell lung cancer

Laboratory investigation, 2014-01, Vol.94 (1), p.107-116

2014

Volltextzugriff (PDF)

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.404-415

2020

Volltextzugriff (PDF)

1 – 25 von 299

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(276)
Mit Volltextzugriff
(261)

Publikationsform

Sprache

Englisch
(297)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(126)
Life Sciences & Biomedicine
(123)
Humans
(109)
Oncology
(89)
Female
(67)
Male
(63)
Aged
(58)
Middle Aged
(57)
Lung Neoplasms - Drug Therapy
(50)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(48)
Adult
(38)
Immunotherapy
(35)
Lung Cancer
(35)
Lung Neoplasms - Pathology
(35)
Aged, 80 And Over
(32)
Tumors
(29)
Lung Neoplasms - Genetics
(28)
Antineoplastic Agents - Therapeutic Use
(27)
Carcinoma, Non-Small-Cell Lung - Pathology
(25)
Carcinoma, Non-Small-Cell Lung - Genetics
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Programmed death ligand-1 expression in non-small cell lung cancer

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Oncolytic virus immunotherapy: future prospects for oncology

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Immuno-thermal ablations - boosting the anticancer immune response

Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non–Small Cell Lung Cancer

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Programmed death ligand-1 expression in non-small cell lung cancer

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Suchergebnisse filtern